Pdt Partners, LLC Coherus Bio Sciences, Inc. Transaction History

Pdt Partners, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$5.86 - $13.23 $133,016 - $300,307	22,699 New	22,699 $164,000
Q1 2022 May 16, 2022	SELL	$10.92 - $16.41 $838,306 - $1.26 Million	-76,768 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$15.81 - $18.99 $999,334 - $1.2 Million	63,209 Added 466.18%	76,768 $1.23 Million
Q3 2021 Nov 15, 2021	SELL	$12.68 - $17.79 $1.65 Million - $2.32 Million	-130,152 Reduced 90.57%	13,559 $218,000
Q2 2021 Aug 16, 2021	SELL	$12.95 - $15.41 $156,824 - $186,615	-12,110 Reduced 7.77%	143,711 $1.99 Million
Q1 2021 May 17, 2021	BUY	$14.42 - $21.39 $265,630 - $394,025	18,421 Added 13.41%	155,821 $2.28 Million
Q4 2020 Feb 16, 2021	SELL	$16.56 - $18.94 $3,146 - $3,598	-190 Reduced 0.14%	137,400 $2.39 Million
Q3 2020 Nov 16, 2020	BUY	$17.41 - $19.89 $2.4 Million - $2.74 Million	137,590 New	137,590 $2.52 Million
Q2 2020 Aug 14, 2020	SELL	$14.43 - $19.16 $386,348 - $512,989	-26,774 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$11.67 - $22.53 $36,690 - $70,834	3,144 Added 13.31%	26,774 $434,000
Q4 2019 Feb 14, 2020	BUY	$16.33 - $21.37 $385,877 - $504,973	23,630 New	23,630 $425,000

135

77.9M

40.7K

50.1K

Ticker CHRS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,724,600
Market Cap $122M
Description
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...

Get notified when there are updates to the investment portfolio of Pdt Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Pdt Partners, LLC with notifications on news.